ClinicalTrials.gg
Enrolling by invitationNCT07373119FRAGICORUpdated Jan 28, 2026

Improving Frailty in Patients With Stable Ischemic Heart Disease

An interventional study of physiotherapy in Coronary Heart Disease, sponsored by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina. Enrolling by invitation at 1 site in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to improve the frailty in old patients who have a cardiac disease .

Researchers will determine the improvement in the instability and the strength along twelve sessions based on guided exercises and mobility techniques made by physiotherapists. Research team will also evaluate the medications and diet, as well as laboratory and clinical tests.

Read the detailed description

Intitial visit to measure quality of life, instability and strenght, followed by twelve sessions, one each week will be performed

02

Conditions studied

  • Coronary Heart Disease

Keywords

  • frailty
  • coronary heart disease
  • elderly
03

In context

Coronary Disease

1,520 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

This study's planned enrollment of 60 is below the median of 160 across 778 interventional studies indexed under Coronary Disease.

Browse Coronary Disease studies →

Lead sponsor

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina is the lead sponsor of 161 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 70 years
  • Diagnosis of coronary artery disease (International Classification Diseases (ICD)-10 I20-I25)
  • Canadian Cardiovascular Society Class I
  • Low cardiovascular risk according to exclusion criteria

Exclusion criteria

Exclusion Criteria:

  • Inability or refusal to provide (advanced dementia, severe psychiatric illness)
  • Inability to perform protocol procedures
  • Severe mobility-limiting conditions (Parkinson's disease, progressive neurological disorders, disabling joint disease)
  • Recent (\<6 months) unstable angina, myocardial infarction, coronary revascularization or angioplasty
  • Deep venous thrombosis or pulmonary embolism in the last 6 months
  • Recent stroke (\<6 months)
  • Heart failure in New York Heart Assocaition functional status () III-IV
  • \< 50%
  • Symptomatic valvular heart disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Patients with stable coronary heart disease

    older than 70 years, idependents in ADL

    Other: physiotherapy

Interventions

  • Otherphysiotherapy

    Primary care based physiotherapy groups

06

What researchers measure

Primary outcomes

  1. Short Physical Performance Battery (SPPB) components (balance, gait speed, chair rise)

    Improvement in baseline values: each of the three component scores \<= 4 points, and tests consists of: balance test, Gait speed and chair-stand tests. Maximum possible is 12 points and under 10 points means frailty

    Time frame: From enrollment to the end of treatment ending after 12 weeks.

Secondary outcomes

  1. Euroqol5D Goldberg Anxiety and Depression Scale Number of falls throughout the study Major Cardiovascular events Adherence to the program

    Euroqol5D measures the Quality of life through an Analogic Visual Scale, which ranks from 0 (worst) to100(best) Goldberg anxiety and depression scales measure the probabilty of suffering from anxiety or depression. The tests consist in a total of 9 questions for each dimension. A score of \>=4 in any of the dimensions suggest pathology. Adherence to the program will be evbaluated counting the attendance to the sessions. More than 9 sessions will be considerated good adherence

    Time frame: from the baseline to 12 weeks of intervention

07

Study locations

1 site
  • Primary Care Centers
    Barcelona, Select... 08007, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07373119
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Oct 1, 2025
Primary completion
Dec 30, 2025
Completion
Dec 31, 2026 (estimated)
Last update
Jan 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion